After more than 25 years working with biotech innovators, I’ve learned that the real value of a patent family lies in the inventive scope where your science, legal strategy, and innovation truly meet . That intersection is what I call the patent sweet spot . So, what exactly is the sweet spot? It’s the range of claim scope that matches the working examples in your application — broad enough to protect what matters commercially, but grounded enough in data to avoid overreach

Innovation, collaboration, and thoughtful IP strategy, that’s what built Invitrogen’s success. And it’s still what drives the best...

Every biotech CEO says it. “We are committed to strong patents.” But here’s the uncomfortable truth: words don’t build patent fortresses....

Why Your Biotech Patent Keeps Getting Rejected, and What to Do About It. If your biotech patent application keeps getting rejected, it’s...

“Bio/pharma funding deal data in H1 2025 reveals a troubling downward shift starting in February.” Investment in bio/pharma was down in...

Struggling to get tough biotech patents allowed? A reactive, traditional "strategy" often fails. Try these 4 proactive, effective...

Biotech products and processes evolve over time. This can cause a misalignment between your issued/pending patent claims, and your...

Too many biotech companies treat IP like a checkbox. Smart ones prune ruthlessly—and build value, not just volume: Prune entire families...

INTRODUCTION Executives usually ask these quantitative but high-level questions: How much money did we spend on patent work this year?...

As a biotech company, much of your value is in (pre-revenue) and/or protected by (post-revenue) your intellectual property. As you...

Common misconceptions about patent rights: In my decades of counseling life sciences companies, I have found that many inventors and...

When should we assure we have FTO for our private biotech company? Summary: FTO for a private biotech company is typically a multi-stage...